Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Huperzine A CR Tablets Safety and Efficacy In Mild-Moderate Alzheimer’s Dementia
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2025
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 30, 2018
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable